^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Tubulin polymerization promoter

    Related drugs:
    13h
    CAPT-HN: Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov)
    P2, N=50, Enrolling by invitation, SWOG Cancer Research Network | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    carboplatin • paclitaxel • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
    16h
    INS-ESCC-CT: Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC (clinicaltrials.gov)
    P2, N=118, Not yet recruiting, Sichuan University
    New P2 trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel
    2d
    Short title: A novel concept for local treatment of the elderly and fragile women with advanced ovarian cancer. (2025-522269-30-00)
    P1/2, N=10, Recruiting, Odense University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin
    2d
    An In-Field Recurrent Cervical Cancer Case After Chemoradiotherapy With a Marked Response to Pembrolizumab Combined With TC (Paclitaxel-Carboplatin) Therapy: A Case Report. (PubMed, Cureus)
    Pembrolizumab combined with TC (paclitaxel-carboplatin) therapy may be an effective treatment option for selected patients with unresectable in-field recurrent cervical cancer. Further evidence is required to clarify the optimal duration of combination therapy and the timing of transition to immune checkpoint inhibitor maintenance.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    6d
    Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=126, Completed, Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Mar 2024 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    utidelone IV (UTD1)
    7d
    CPO-100-US-101: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=34, Terminated, Conjupro Biotherapeutics, Inc. | N=126 --> 34 | Active, not recruiting --> Terminated; Business Decision
    Enrollment change • Trial termination
    |
    albumin-bound docetaxel (CPO100)
    9d
    Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma. (PubMed, EMBO Mol Med)
    After carboplatin and paclitaxel treatment, a combination chemotherapy used in human LUSC, we detected increased neutrophils in circulation, spleen and tumors, and increased Bcl-xL in neutrophils and TANs. Bcl-xL blockade decreased the pool of Bcl-xL-high TANs and synergized with chemotherapy. Altogether, our results suggest distinct outcomes for targeting TANs in different tumor types and reinforce the concept of repurposing BH3 mimetics against cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BCL2L1 (BCL2-like 1) • SOX2
    |
    KRAS G12D • TP53 wild-type • KRAS G12
    |
    carboplatin • paclitaxel
    9d
    Pt(II) Complex with FGFR4 Specificity as a Targeted Drug Conjugate for the Treatment of Hepatocellular Carcinoma. (PubMed, Inorg Chem)
    Guided by the targeted drug conjugate (TDC) strategy, the pharmacophore of lenvatinib was modified by incorporating DN604 (C6H10N2O5Pt), a carboplatin analogue, to generate a Pt(II) complex Len-604 (C30H33ClN8O9Pt). It exhibited potent cytotoxicity against human hepatocellular carcinoma cell lines HUH-7 and SMMC-7721, with IC50 values of 5.62 and 5.64 μM, respectively. Significantly, in HUH-7 xenograft models, Len-604 exhibited stronger antitumor activity than lenvatinib, while showing lower toxicity than cisplatin and its physical mixture with lenvatinib.
    Journal
    |
    FGFR4 (Fibroblast growth factor receptor 4)
    |
    cisplatin • carboplatin • Lenvima (lenvatinib)
    10d
    RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode (clinicaltrials.gov)
    P2, N=126, Completed, Mapreg | Active, not recruiting --> Completed
    Trial completion
    10d
    Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Nov 2026
    Trial completion date
    |
    MammaPrint®
    |
    carboplatin • albumin-bound paclitaxel
    11d
    A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=14, Completed, Dana-Farber Cancer Institute | N=28 --> 14 | Trial completion date: Jan 2016 --> Jan 2026
    Enrollment change • Trial completion date
    |
    carboplatin